JAK2 and Chronic Eosinophilic Leukemia, Not Otherwise Specified: As such, JAK2 inhibition will be an excellent strategy to manage F/P(+) CEL patients who have become resistant or intolerant to Imatinib/dasatinib and other potent tyrosine kinase inhibitors.